ストックスクリーナーアプリを入手
3.80
4.68%
0.17
前日終値:
$3.63
開ける：
$3.65
24時間の取引高:
146.73K
Relative Volume:
0.91
時価総額：
$64.83M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+10.79%
1か月 パフォーマンス:
-8.87%
6か月 パフォーマンス:
+18.38%
1年 パフォーマンス:
-28.17%
1日の値動き範囲:
$3.57
$3.83
1週間の範囲:
$3.415
$3.83
52週間の値動き範囲:
$2.87
$5.38
Mural Oncology Plc Stock (MURA) Company Profile
MURA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
3.80 | 64.83M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-04-04 | 開始されました | Morgan Stanley | Overweight |
Mural Oncology Plc (MURA) 最新ニュース
Mural Oncology enters agreement for share sales By Investing.com - Investing.com South Africa
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical - EIN News
Mural Oncology CEO Caroline Loew sells shares worth $14,491 - Investing.com
Mural oncology officer sells shares worth $9,308 - Investing.com India
Mural oncology officer sells shares worth $9,308 By Investing.com - Investing.com South Africa
Mural Oncology's chief medical officer sells $51,293 in shares - Investing.com India
Mural Oncology’s chief medical officer sells $51,293 in shares - Investing.com
Exclusive: Mural Oncology Unveils Next-Gen Cancer Treatment Strategy at Major Healthcare Conference - StockTitan
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Mural Oncology plc (NASDAQ:MURA) Short Interest Update - MarketBeat
Alkermes plc (ALKS) reports earnings - Quartz
Mural Oncology (NASDAQ:MURA) Trading 8.8% HigherHere's What Happened - MarketBeat
Mural Oncology (NASDAQ:MURA) Trading 8.8% Higher – Here’s Why - Defense World
Jones Trading sets $16 target on Mural Oncology stock By Investing.com - Investing.com Nigeria
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Geode Capital Management LLC Purchases 4,731 Shares of Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts - The Manila Times
Mural Oncology Expands Pipeline with Two Novel Cancer Therapies, Advances Key Clinical Trials - StockTitan
Mural Oncology's chief legal officer sells $8,354 in shares By Investing.com - Investing.com Australia
Mural Oncology's chief legal officer sells $8,354 in shares - Investing.com India
Fmr LLC Grows Stake in Mural Oncology plc (NASDAQ:MURA) - Defense World
2025 will be a big year for Mural Oncology's drugs in development - The Business Journals
BNP Paribas Financial Markets Lowers Stake in Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology stock hits 52-week low at $2.87 By Investing.com - Investing.com UK
Mural Oncology CEO Caroline Loew sells shares worth $9,394 - Investing.com
Mural Oncology CEO Caroline Loew sells shares worth $9,394 By Investing.com - Investing.com UK
Mural Oncology plc (NASDAQ:MURA) Shares Sold by Verition Fund Management LLC - MarketBeat
Mural Oncology GAAP EPS of -$1.84; reaffirms financial guidance - MSN
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mural Oncology Awards Key Talent with Stock Options and RSU Inducement Grants - StockTitan
Analysts Give Strong Buy Rating To This Undervalued Medical Stock (MURA) With Up To 350% Of Share Price Upside - Yahoo Finance
Alkermes to Participate in Upcoming Investor Conferences - Quantisnow
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Rodman & Renshaw Initiates Coverage of Mural Oncology (MURA) with Buy Recommendation - MSN
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer - The Manila Times
Mural Oncology's Cancer Drug Shows 33% Response Rate in Melanoma Trial Data | MURA Stock News - StockTitan
HC Wainwright Raises Earnings Estimates for Mural Oncology - Defense World
HC Wainwright Predicts Stronger Earnings for Mural Oncology - MarketBeat
MURAMural Oncology plc Ordinary Shares Latest Stock News & Market Updates - StockTitan
Armistice Capital, LLC Increases Stake in Mural Oncology PLC - GuruFocus.com
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress - The Manila Times
Mural Oncology plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mural Oncology Reports 38% Lower Net Loss, Hits Trial Enrollment Milestones in Q3 | MURA Stock News - StockTitan
HC Wainwright Reaffirms "Buy" Rating for Mural Oncology (NASDAQ:MURA) - MarketBeat
Mural Oncology to Participate in Two Upcoming Investor Conferences - The Manila Times
Mural Oncology (MURA) to Present at Major Healthcare Investor Conferences | MURA Stock News - StockTitan
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - The Manila Times
Mural Oncology Reports Promising Cancer Trial Data, Plans Key 2025 Readouts | MURA Stock News - StockTitan
Mural Oncology Plc (MURA) 財務データ
Mural Oncology Plc (MURA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Mural Oncology Plc (MURA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Keson-Brookes Maiken | See Remarks |
Mar 05 '25 |
Sale |
3.45 |
1,469 |
5,068 |
73,564 |
| Keson-Brookes Maiken | See Remarks |
Mar 04 '25 |
Sale |
3.36 |
1,262 |
4,240 |
75,033 |
| Loew Caroline | Chief Executive Officer |
Mar 04 '25 |
Sale |
3.36 |
4,313 |
14,492 |
305,590 |
2.14%
2.83%
大文字化:
|
ボリューム (24 時間):